Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration

Table 1

Demographics of 30 eligible patients in retrospective study.

Age at entry (years)	46.1 ± 14.8
Gender (M/F)	12/18
Disease extent
Extensive	5
Left-sided	12
Proctitis	13
Dose of prior mesalazine (Pentasa)
2250 mg	15
3000 mg	3
4000 mg	12
Dose of switched mesalazine (Asacol)
2400 mg	12
3600 mg	18